Mackenzie Financial Corp Sage Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

$65 Billion
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$40.65 - $59.54 $5,243 - $7,680	-129 Reduced 2.55%	4,925 $231,000
Q1 2023 Apr 24, 2023	SELL	$37.27 - $46.57 $7,193 - $8,988	-193 Reduced 3.68%	5,054 $212,000
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $5,441 - $7,370	-169 Reduced 3.12%	5,247 $200,000
Q3 2022 Oct 07, 2022	BUY	$32.28 - $43.27 $174,828 - $234,350	5,416 New	5,416 $212,000
Q2 2022 Aug 10, 2022	SELL	$27.52 - $37.99 $1.35 Million - $1.87 Million	-49,146 Closed	0 $0

Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $33,781 - $50,281	-1,100 Reduced 2.19%	49,146 $1.63 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $48,178 - $61,243	1,300 Added 2.66%	50,246 $2.14 Million
Q3 2021 Nov 08, 2021	BUY	$40.26 - $57.37 $378,444 - $539,278	9,400 Added 23.77%	48,946 $2.17 Million
Q2 2021 Aug 11, 2021	BUY	$54.88 - $79.29 $900,032 - $1.3 Million	16,400 Added 70.85%	39,546 $2.25 Million
Q1 2021 May 14, 2021	BUY	$70.65 - $96.76 $1.03 Million - $1.41 Million	14,573 Added 169.99%	23,146 $1.73 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $481 - $1,238	8 Added 0.09%	8,573 $619,000
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $9,960 - $13,487	71 Added 0.84%	8,565 $1.2 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $315,226 - $365,630	1,997 Added 30.74%	8,494 $1.56 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $333,558 - $611,069	3,734 Added 135.14%	6,497 $1.03 Million
Q4 2018 Feb 06, 2019	SELL	$81.94 - $139.71 $1.18 Million - $2.01 Million	-14,412 Reduced 83.91%	2,763 $265,000
Q3 2018 Nov 15, 2018	BUY	$138.11 - $169.04 $205,231 - $251,193	1,486 Added 9.47%	17,175 $2.43 Million
Q2 2018 Aug 13, 2018	BUY	$140.36 - $175.76 $1.91 Million - $2.39 Million	13,576 Added 642.5%	15,689 $2.46 Million
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $321,492 - $406,393	2,113 New	2,113 $340,000

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

Vanguard Group Inc Valley Forge, PA

5.75M
Shares

$62 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.48M
Shares

$59.1 Million
1.65% of portfolio
Black Rock Inc. New York, NY

4.89M
Shares

$52.7 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

4.75M
Shares

$51.2 Million
0.02% of portfolio
State Street Corp Boston, MA

4.49M
Shares

$48.5 Million
0.0% of portfolio

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account